A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

Esther Bastiaannet, Jackie Charman, Tom Børge Johannesen, Simone Schrodi, Sabine Siesling, Liesbet Van Eycken, Paul M. Walsh, Riccardo A. Audisio, Petra G. Boelens, Isabel T. Rubio, Nick Jones, Jan Lewis, Cornelis J.H. van de Velde* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
52 Downloads (Pure)

Abstract

Background: Despite guideline recommendations, reports suggest that a proportion of patients with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC) might not receive endocrine therapy. The aims of this study were to estimate the proportion of postmenopausal patients with an initial (primary) diagnosis of HR-positive LA/MBC in Europe, and to assess the administration of endocrine treatment in these patients. Materials and Methods: Fourteen national and regional cancer registries across Europe were invited to participate in this observational study. Six registries each provided anonymized clinical information on > 5000 postmenopausal women with breast cancer diagnosed between January 2000 and December 2014, including age at diagnosis, estrogen and/or progesterone receptor status, disease stage, and receipt of endocrine therapy. The proportion of patients with an initial diagnosis of HR-positive LA/MBC and, of these, the proportion who received endocrine therapy, was calculated. Results: Registries from Belgium, England, Ireland, Norway, The Netherlands, and Munich, Germany provided data. In total, 316,680 postmenopausal women were diagnosed with breast cancer, including 244,268 with known HR status and disease stage. Of these patients, 19,002 (7.8%) had a primary diagnosis of HR-positive LA/MBC. This proportion ranged from 5.4% (N = 4484) in England to 12.7% (N = 4085) in Germany. Most of these patients (n = 14,157; 74.5%) received endocrine treatment, ranging from 55.5% (n = 445) in Norway to 88.1% (n = 443) in Belgium. Conclusion: These results indicate that a sizeable proportion of postmenopausal patients in Europe received a primary diagnosis of HR-positive LA/MBC, and that almost three-quarters received subsequent endocrine therapy as per guideline recommendations.

Original languageEnglish
Pages (from-to)e613-e619
JournalClinical breast cancer
Volume18
Issue number4
Early online date29 Nov 2017
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Observational Studies
Hormones
Breast Neoplasms
Registries
Belgium
Norway
England
Therapeutics
Germany
Guidelines
Progesterone Receptors
Ireland
Estrogen Receptors
Netherlands
Neoplasms

Keywords

  • Endocrine treatment
  • European comparison
  • Locally advanced/metastatic breast cancer
  • Population-based cancer registries

Cite this

Bastiaannet, Esther ; Charman, Jackie ; Johannesen, Tom Børge ; Schrodi, Simone ; Siesling, Sabine ; Van Eycken, Liesbet ; Walsh, Paul M. ; Audisio, Riccardo A. ; Boelens, Petra G. ; Rubio, Isabel T. ; Jones, Nick ; Lewis, Jan ; van de Velde, Cornelis J.H. / A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer. In: Clinical breast cancer. 2018 ; Vol. 18, No. 4. pp. e613-e619.
@article{f1aacef96b3e46e3b0a57a8c6cbd2746,
title = "A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer",
abstract = "Background: Despite guideline recommendations, reports suggest that a proportion of patients with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC) might not receive endocrine therapy. The aims of this study were to estimate the proportion of postmenopausal patients with an initial (primary) diagnosis of HR-positive LA/MBC in Europe, and to assess the administration of endocrine treatment in these patients. Materials and Methods: Fourteen national and regional cancer registries across Europe were invited to participate in this observational study. Six registries each provided anonymized clinical information on > 5000 postmenopausal women with breast cancer diagnosed between January 2000 and December 2014, including age at diagnosis, estrogen and/or progesterone receptor status, disease stage, and receipt of endocrine therapy. The proportion of patients with an initial diagnosis of HR-positive LA/MBC and, of these, the proportion who received endocrine therapy, was calculated. Results: Registries from Belgium, England, Ireland, Norway, The Netherlands, and Munich, Germany provided data. In total, 316,680 postmenopausal women were diagnosed with breast cancer, including 244,268 with known HR status and disease stage. Of these patients, 19,002 (7.8{\%}) had a primary diagnosis of HR-positive LA/MBC. This proportion ranged from 5.4{\%} (N = 4484) in England to 12.7{\%} (N = 4085) in Germany. Most of these patients (n = 14,157; 74.5{\%}) received endocrine treatment, ranging from 55.5{\%} (n = 445) in Norway to 88.1{\%} (n = 443) in Belgium. Conclusion: These results indicate that a sizeable proportion of postmenopausal patients in Europe received a primary diagnosis of HR-positive LA/MBC, and that almost three-quarters received subsequent endocrine therapy as per guideline recommendations.",
keywords = "Endocrine treatment, European comparison, Locally advanced/metastatic breast cancer, Population-based cancer registries",
author = "Esther Bastiaannet and Jackie Charman and Johannesen, {Tom B{\o}rge} and Simone Schrodi and Sabine Siesling and {Van Eycken}, Liesbet and Walsh, {Paul M.} and Audisio, {Riccardo A.} and Boelens, {Petra G.} and Rubio, {Isabel T.} and Nick Jones and Jan Lewis and {van de Velde}, {Cornelis J.H.}",
year = "2018",
month = "8",
doi = "10.1016/j.clbc.2017.11.019",
language = "English",
volume = "18",
pages = "e613--e619",
journal = "Clinical breast cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

Bastiaannet, E, Charman, J, Johannesen, TB, Schrodi, S, Siesling, S, Van Eycken, L, Walsh, PM, Audisio, RA, Boelens, PG, Rubio, IT, Jones, N, Lewis, J & van de Velde, CJH 2018, 'A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer', Clinical breast cancer, vol. 18, no. 4, pp. e613-e619. https://doi.org/10.1016/j.clbc.2017.11.019

A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer. / Bastiaannet, Esther; Charman, Jackie; Johannesen, Tom Børge; Schrodi, Simone; Siesling, Sabine; Van Eycken, Liesbet; Walsh, Paul M.; Audisio, Riccardo A.; Boelens, Petra G.; Rubio, Isabel T.; Jones, Nick; Lewis, Jan; van de Velde, Cornelis J.H. (Corresponding Author).

In: Clinical breast cancer, Vol. 18, No. 4, 08.2018, p. e613-e619.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

AU - Bastiaannet, Esther

AU - Charman, Jackie

AU - Johannesen, Tom Børge

AU - Schrodi, Simone

AU - Siesling, Sabine

AU - Van Eycken, Liesbet

AU - Walsh, Paul M.

AU - Audisio, Riccardo A.

AU - Boelens, Petra G.

AU - Rubio, Isabel T.

AU - Jones, Nick

AU - Lewis, Jan

AU - van de Velde, Cornelis J.H.

PY - 2018/8

Y1 - 2018/8

N2 - Background: Despite guideline recommendations, reports suggest that a proportion of patients with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC) might not receive endocrine therapy. The aims of this study were to estimate the proportion of postmenopausal patients with an initial (primary) diagnosis of HR-positive LA/MBC in Europe, and to assess the administration of endocrine treatment in these patients. Materials and Methods: Fourteen national and regional cancer registries across Europe were invited to participate in this observational study. Six registries each provided anonymized clinical information on > 5000 postmenopausal women with breast cancer diagnosed between January 2000 and December 2014, including age at diagnosis, estrogen and/or progesterone receptor status, disease stage, and receipt of endocrine therapy. The proportion of patients with an initial diagnosis of HR-positive LA/MBC and, of these, the proportion who received endocrine therapy, was calculated. Results: Registries from Belgium, England, Ireland, Norway, The Netherlands, and Munich, Germany provided data. In total, 316,680 postmenopausal women were diagnosed with breast cancer, including 244,268 with known HR status and disease stage. Of these patients, 19,002 (7.8%) had a primary diagnosis of HR-positive LA/MBC. This proportion ranged from 5.4% (N = 4484) in England to 12.7% (N = 4085) in Germany. Most of these patients (n = 14,157; 74.5%) received endocrine treatment, ranging from 55.5% (n = 445) in Norway to 88.1% (n = 443) in Belgium. Conclusion: These results indicate that a sizeable proportion of postmenopausal patients in Europe received a primary diagnosis of HR-positive LA/MBC, and that almost three-quarters received subsequent endocrine therapy as per guideline recommendations.

AB - Background: Despite guideline recommendations, reports suggest that a proportion of patients with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC) might not receive endocrine therapy. The aims of this study were to estimate the proportion of postmenopausal patients with an initial (primary) diagnosis of HR-positive LA/MBC in Europe, and to assess the administration of endocrine treatment in these patients. Materials and Methods: Fourteen national and regional cancer registries across Europe were invited to participate in this observational study. Six registries each provided anonymized clinical information on > 5000 postmenopausal women with breast cancer diagnosed between January 2000 and December 2014, including age at diagnosis, estrogen and/or progesterone receptor status, disease stage, and receipt of endocrine therapy. The proportion of patients with an initial diagnosis of HR-positive LA/MBC and, of these, the proportion who received endocrine therapy, was calculated. Results: Registries from Belgium, England, Ireland, Norway, The Netherlands, and Munich, Germany provided data. In total, 316,680 postmenopausal women were diagnosed with breast cancer, including 244,268 with known HR status and disease stage. Of these patients, 19,002 (7.8%) had a primary diagnosis of HR-positive LA/MBC. This proportion ranged from 5.4% (N = 4484) in England to 12.7% (N = 4085) in Germany. Most of these patients (n = 14,157; 74.5%) received endocrine treatment, ranging from 55.5% (n = 445) in Norway to 88.1% (n = 443) in Belgium. Conclusion: These results indicate that a sizeable proportion of postmenopausal patients in Europe received a primary diagnosis of HR-positive LA/MBC, and that almost three-quarters received subsequent endocrine therapy as per guideline recommendations.

KW - Endocrine treatment

KW - European comparison

KW - Locally advanced/metastatic breast cancer

KW - Population-based cancer registries

UR - http://www.scopus.com/inward/record.url?scp=85038884433&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2017.11.019

DO - 10.1016/j.clbc.2017.11.019

M3 - Article

AN - SCOPUS:85038884433

VL - 18

SP - e613-e619

JO - Clinical breast cancer

JF - Clinical breast cancer

SN - 1526-8209

IS - 4

ER -